Document is current

Article History

Received: 8 March 2023

Accepted: 20 April 2023

First Online: 10 May 2023

Declarations

:

: The patient has provided written consent to use his clinical data and biomaterial for future research purposes, as part of the Amsterdam Dementia Cohort, which was approved by the Medical Ethics Committee of the VU medical center under the reference number 2016/061. Before death, the patient’s next of kin gave written informed consent for brain donation to the NEwTON cohort of the Netherlands Brain Bank (NBB), according to the ethical guidelines of brain banking. The NBB has been approved by the Medical Ethics Committee of the VU medical center under the reference number 2009/148. After death, the brain autopsy has eventually been performed by the Amsterdam Medical Centers Department of Pathology instead of the NBB due to logistical reasons, after consent of the family.

: Before submission, all closest next of kin gave written informed consent to submit and publish this case report. They understand that all materials are published without a name attached but that anonymity is not guaranteed.

: PS has received consultancy fees (paid to the institutions) from AC Immune, Alkermes, Alnylam, Alzheon, Anavex, Axoltis, Brainstorm Cell, Cortexyme, Denali, EIP, ImmunoBrain Checkpoint, GemVax, Genentech, Green Valley, Novartis, Novo Nordisk, PeopleBio, Renew LLC, and Roche. He received payment or honoraria from Nutricia. He is a PI of studies with AC Immune, CogRx, FUJI-film/Toyama, IONIS, UCB, and Vivoryon. He is a part-time employee of Life Sciences Partners Amsterdam, and he serves on the board of New Amsterdam Pharma. CET is a member of the Innogenetics International Advisory Boards of Fujirebio/Innogenetics and Roche. She has received research reagents from ADxNeurosciences and Euroimmun and has a collaboration contract with ADx Neurosciences and with Quanterix. She has performed contract research or received grants from AC Immune, AxonNeurosciences, Biogen, Boehringer, Brainstorm Therapeutics, Celgene, CogRx, EIP Pharma, Esai, Fujirebio, Janssen prevention center, PeopleBio, Probiodrug, Roche, Toyama, and Vivoryon. Research from CET is supported by the European Commission (Marie Curie International Training Network, JPND), Health Holland, the Dutch Research Council (ZonMW), The Weston Brain Institute, Alzheimer Netherlands, and Alzheimer Association. FB is supported by the NIHR biomedical research center at UCLH. RAS has been a paid consultant to Biogen (Cambridge, MA, USA) and Lundbeck (Copenhagen, Denmark). He is a member of the Board of Directors of King-Devick Technologies, Inc. (Chicago, IL, USA), and he receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. (Lutz, FL, USA). He was a member of the Medical Science Committee for the National Collegiate Athletic Association Student-Athlete Concussion Injury Litigation. EGBV has received consultancy fees (paid to the institution) from Biogen, Brainstorm Therapeutics, ImmunoBrain Checkpoint, New Amsterdam Pharma, ReMynd and Treeway, Vivoryon, and Vigil Neuroscience. He is the PI of studies with ACImmune, CogRx, Green Valley, IONIS, Janssen, Roche, Rodin Therapeutics, Sanofi, UCB, and Vivoryon. JJMH is the Editor-in-Chief of Acta Neuropathologica Communications.